1 卫生部新闻办公室. 第三次全国死因调查主要情况[J].

中国肿瘤，2008，17：344-345.

2 Yang G，Wang Y，Zeng Y，et al. Rapid health

transition in China，1990-2010：findings from the

Global Burden of Disease Study 2010[J]. Lancet，2013，

381：1987-2015.

3 Tissue plasminogen activator for acute ischemic

st roke. The National Institute of Neurological

Disorders and Stroke rt-PA Stroke Study Group[J]. N

Engl J Med，1995，333：1581-1587.

4 Hacke W，Kaste M，Bluhmki E，et al. Thrombolysis

with alteplase 3 to 4. 5 hours after acute ischemic

stroke[J]. N Engl J Med，2008，359：1317-1329.

5 Davis SM，Donnan GA，Parsons MW，et al. Effects

of alteplase beyond 3 h after stroke in the Echoplanar

Imaging Thrombolytic Evaluation Trial (EPITHET)：a

placebo-controlled randomised trial[J]. Lancet Neurol，

2008，7：299-309.

6 Wa h lg r en N，Ahmed N，Dáva l o s A，e t a l .

Thrombolysis with alteplase 3-4. 5 h after acute

ischaemic stroke (SITS-ISTR)：an observational

study[J]. Lancet，2008，372：1303-1309.

7 Saver JL，Altman H. Relationship between neurologic

deficit severity and final functional outcome shifts

and strengthens during first hours after onset[J].

Stroke，2012，43：1537-1541.

8 Dávalos A，Toni D，Iweins F，et al. Neurological

deterioration in acute ischemic stroke：potential

predictors and associated factors in the European

cooperative acute stroke study (ECASS) Ⅰ[J]. Stroke，

1999，30：2631-2636.

9 Kim JM，Moon J，Ahn SW，et al. The etiologies of

early neurological deterioration after thrombolysis

and risk factors of ischemia progression[J]. J Stroke

Cerebrovasc Dis，2016，25：383-388.

10 Zinkstok SM，Beenen LF，Majoie CB，et al. Early

deterioration after thrombolysis plus aspirin in acute

stroke：a post hoc analysis of the Antiplatelet Therapy

in Combination with Recombinant t-PA Thrombolysis

in Ischemic Stroke trial[J]. Stroke，2014，45：3080-

3082.

11 Hacke W，Kaste M，Fieschi C，et al. Randomised

double-blind placebo-controlled trial of thrombolytic

therapy with intravenous alteplase in acute ischaemic

stroke (ECASS Ⅱ). Second European-Australasian

Acute Stroke Study Investigators[J]. Lancet，1998，

352：1245-1251.

12 Wa h lg r en N，Ahmed N，Dáva l o s A，e t a l .

Thrombolysis with alteplase for acute ischaemic stroke

in the Safe Implementation of Thrombolysis in Stroke-

Monitoring Study (SITS-MOST)：an observational

study[J]. Lancet，2007，369：275-282.

13 Mor i M，Naganuma M，Okada Y，et al. Early

neurological deterioration within 24 hours after

intravenous rt-PA therapy for stroke patients：the

Stroke Acute Management with Urgent Risk Factor

Assessment and Improvement rt-PA Registry[J].

Cerebrovasc Dis，2012，34：140-146.

14 Awadh M，MacDougall N，Santosh C，et al. Early

recurrent ischemic stroke complicating intravenous

thrombolysis for stroke：incidence and association

with atrial fibrillation[J]. Stroke，2010，41：1990-1995.

15 Nanri Y，Yakushiji Y，Hara M，et al. Stroke scale

items associated with neurologic deterioration within

24 hours after recombinant tissue plasminogen

activator therapy[J]. J Stroke Cerebrovasc Dis，2013，

22：1117-1124.

16 Simonsen CZ，Schmitz ML，Madsen MH，et al. Early

neurological deterioration after thrombolysis：Clinical

and imaging predictors[J]. Int J Stroke，2016，11：776-

782.

17 Siegler JE，Martin-Schild S. Early neurological

deterioration (END) after stroke：the END depends

on the definition[J]. Int J Stroke，2011，6：211-212.

18 Seners P，Turc G，Oppenheim C，et al. Incidence，

causes and predictors of neurological deterioration

occurring within 24 h following acute ischaemic

stroke：a systematic review with pathophysiological

implications[J]. J Neurol Neurosurg Psychiatry，2015，

86：87-94.

19 Wardlaw JM，Murray V，Berge E，et al. Recombinant

tissue plasminogen activator for acute ischaemic

stroke：an updated systematic review and metaanalysis[

J]. Lancet，2012，379：2364-2372.

20 Strbian D，Sairanen T，Meretoja A，et al. Patient

outcomes from symptomatic intracerebral hemorrhage

after stroke thrombolysis[J]. Neurology，2011，77：

341-348.

21 Tong X，George MG，Yang Q，et al. Predictors

of in-hospital death and symptomatic intracranial

hemorrhage in patients with acute ischemic stroke

treated with thrombolytic therapy：Paul Coverdell

Acute Stroke Registry 2008-2012[J]. Int J Stroke，2014，

9：728-734.

22 Desilles JP，Meseguer E，Labreuche J，et al. Diabetes

mellitus，admission glucose，and outcomes after

stroke thrombolysis：a registry and systematic

review[J]. Stroke，2013，44：1915-1923.

23 Bentley P，Ganesalingam J，Carlton Jones AL，et al.

Prediction of stroke thrombolysis outcome using CT

brain machine learning[J]. Neuroimage Clin，2014，4：

中国卒中杂志 2017年２月 第12卷 第２期 197

635-640.

24 Dubey N，Bakshi R，Wasay M，et al. Early computed

tomography hypodensity predicts hemorrhage after

intravenous tissue plasminogen activator in acute

ischemic stroke[J]. J Neuroimaging，2001，11：184-

188.

25 Whiteley WN，Emberson J，Lees KR，et al. Risk

of intracerebral haemorrhage with alteplase after

acute ischaemic stroke：a secondary analysis of

an individual patient data meta-analysis[J]. Lancet

Neurol，2016，15：925-933.

26 Treadwell SD，Thanvi B. Malignant middle cerebral

artery (MCA) infarction：pathophysiology，diagnosis

and management[J]. Postgrad Med J，2010，86：235-

242.

27 Battey TW，Karki M，Singhal AB，et al. Brain edema

predicts outcome after nonlacunar ischemic stroke[J].

Stroke，2014，45：3643-3648.

28 Kobayashi M，Tanaka R，Yamashiro K，et al. Preexisting

mobile cardiac thrombus and the risk of early

recurrent embolism after intravenous thrombolysis：a

case report[J]. J Stroke Cerebrovasc Dis，2015，24：

e161-e163.

29 Kamal H，Mowla A，Farooq S，et al. Recurrent

ischemic stroke can happen in stroke patients very

early after intravenous thrombolysis[J]. J Neurol Sci，

2015，358：496-497.

30 Kahles T，Mono ML，Heldner MR，et al. Repeated

intravenous thrombolysis for early recurrent stroke：

challenging the exclusion criterion[J]. Stroke，2016，

47：2133-2135.

31 Jung S，Schindler K，Findling O，et al. Adverse

effect of early epileptic seizures in patients receiving

endovascular therapy for acute stroke[J]. Stroke，2012，

43：1584-1590.

32 Alvarez V，Rossetti AO，Papavasileiou V，et al. Acute

seizures in acute ischemic stroke：does thrombolysis

have a role to play?[J]. J Neurol，2013，260：55-61.

33 Seners P，Turc G，Tisserand M，et al. Unexplained

early neurological deterioration after intravenous

thrombolysis：incidence，predictors，and associated

factors[J]. Stroke，2014，45：2004-2009.

34 Tisserand M，Seners P，Turc G，et al. Mechanisms

of unexplained neurological deterioration after

intravenous thrombolysis[J]. Stroke，2014，45：3527-

3534.

35 Reuter B，Gumbinger C，Sauer T，et al. Intravenous

thrombolysis for acute ischaemic stroke in the

elderly：data from the Baden-Wuerttemberg Stroke

Registry[J]. Eur J Neurol，2016，23：13-20.

36 Mione G，Ducrocq X，Thilly N，et al. Outcome

of intravenous recombinant tissue plasminogen

activator for acute ischemic stroke in patients aged

over 80 years[J]. Geriatr Gerontol Int，2016，16：

843-849.

37 Alvarez-Sabín J，Mol ina CA，Montaner J，et

al. Effects of admission hyperglycemia on stroke

outcome in reperfused tissue plasminogen activator--

treated patients[J]. Stroke，2003，34：1235-1241.

38 Ennis SR，Keep RF. Effect of sustained-mild and

transient-severe hyperglycemia on ischemia-induced

blood-brain barrier opening[J]. J Cereb Blood Flow

Metab，2007，27：1573-1582.

39 Hou Q，Zuo Z，Michel P，et al. Influence of chronic

hyperglycemia on cerebral microvascular remodeling：

an in vivo study using per fusion computed

tomography in acute ischemic stroke patients[J].

Stroke，2013，44：3557-3560.

40 Morita N，Harada M，Uno M，et al. Evaluation of

initial diffusion-weighted image findings in acute

stroke patients using a semiquantitative score[J].

Magn Reson Med Sci，2009，8：47-53.

41 Haeusler KG，Gerischer LM，Vatankhah B，et al.

Impact of hospital admission during nonworking

hours on patient outcomes after thrombolysis for

stroke[J]. Stroke，2011，42：2521-2525.

42 Whiteley WN，Slot KB，Fernandes P，et al. Risk

factors for intracranial hemorrhage in acute ischemic

stroke patients treated with recombinant tissue

plasminogen activator：a systematic review and metaanalysis

of 55 studies[J]. Stroke，2012，43：2904-2909.

43 Strbian D，Meretoja A，Putaala J，et al. Cerebral

edema in acute ischemic stroke patients treated with

intravenous thrombolysis[J]. Int J Stroke，2013，8：

529-534.

44 Tiainen M，Meretoja A，Strbian D，et al. Body

temperature，blood infection parameters，and

outcome of thrombolysis-treated ischemic stroke

patients[J]. Int J Stroke，2013，8：632-638.

45 Cermak J，Key NS，Bach RR，et al. C-reactive

protein induces human peripheral blood monocytes to

synthesize tissue factor[J]. Blood，1993，82：513-520.

46 Villemure C，Bushnell MC. Mood inf luences

supraspinal pain processing separately f rom

attention[J]. J Neurosci，2009，29：705-715.

47 Baizabal-Carvallo JF，Alonso-Juarez M，Samson Y.

Clinical deterioration following middle cerebral artery

hemodynamic changes after intravenous thrombolysis

for acute ischemic stroke[J]. J Stroke Cerebrovasc Dis，

2014，23：254-258.

48 We i X E，Zhao YW，Lu J，et a l . Timi ng of

recanalization and outcome in ischemic-stroke

198 Chin J Stroke, Feb 2017, Vol 12, No.2

patients treated with recombinant tissue plasminogen

activator[J]. Acta Radiol，2015，56：1119-1126.

49 Kim YD，Lee JH，Jung YH，et al. Effect of warfarin

withdrawal on thrombolytic treatment in patients with

ischaemic stroke[J]. Eur J Neurol，2011，18：1165-

1170.

50 Lou M，Selim M. Does body weight influence the

response to intravenous tissue plasminogen activator

in stroke patients?[J]. Cerebrovasc Dis，2009，27：84-

90.

51 Kim JT，Park MS，Chang J，et al. Proximal arterial

occlusion in acute ischemic stroke with low NIHSS

scores should not be considered as mild stroke[J].

PLoS One，2013，8：e70996.